Ossama Samuel, MD
Nuclear Cardiology · Brooklyn, NYNPI 1871533109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.
Across 195 payments — averaging $34.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Boehringer Ingelheim$1K
- Bayer$636
- Novartis$623
- AstraZeneca$509
- Merck$473
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $1,107 |
| Boehringer Ingelheim | 18 | $1,046 |
| Bayer | 29 | $636 |
| Novartis | 30 | $623 |
| AstraZeneca | 19 | $509 |
| Merck | 20 | $473 |
| Amgen | 18 | $402 |
| Medtronic(2 entities) | 3 | $330 |
| Pfizer | 7 | $224 |
| Johnson & Johnson | 10 | $219 |
| Terumo Medical Corporation | 2 | $173 |
| Scpharmaceuticals Inc. | 1 | $146 |
| Shockwave Medical, Inc | 1 | $141 |
| Novo Nordisk | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 6 | $108 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $103 |
| Amarin Pharma, Inc. | 1 | $97 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $95 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Bridgebio Pharma, Inc. | 3 | $78 |
| Boston Scientific | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$607
- MitraClip$426
- Mitra Clip system$356
- Kerendia$275
- ClosureFast$158
- PRESSUREWIRE$150
- SYMPLICITY G3$150
- FUROSCIX$146
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$141
- Ozempic$125
- VYNDAQEL$123
- WAINUA$120
- METACROSS OTW$113
How this compares
$6,812 in reported general payments places this provider in the 70th percentile of 21 nuclear cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 185 | $200,338 |
| EntrestoSacubitril/Valsartan | 65 | $100,419 |
| Repatha SureclickEvolocumab | 56 | $74,478 |
| FarxigaDapagliflozin Propanediol | 66 | $72,503 |
| XareltoRivaroxaban | 39 | $48,297 |
| JardianceEmpagliflozin | 50 | $48,061 |
| Praluent PenAlirocumab | 44 | $43,934 |
| WegovySemaglutide | 30 | $39,231 |
| OzempicSemaglutide | 20 | $29,158 |
| VascepaIcosapent Ethyl | 17 | $10,544 |
| Ranolazine ErRanolazine | 64 | $8,610 |
| DapagliflozinDapagliflozin Propanediol | 12 | $8,067 |
| Atorvastatin Calcium | 680 | $7,812 |
| Icosapent Ethyl | 17 | $7,662 |
| Ezetimibe | 373 | $7,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $224 | $200,338185 claims |
| NovartisEntresto | $623 | $100,41965 claims |
| AstraZenecaFarxiga | $509 | $72,50366 claims |
| Novo NordiskWegovy, Ozempic | $125 | $68,38950 claims |
| Johnson & JohnsonXarelto | $219 | $48,29739 claims |
| Boehringer IngelheimJardiance | $1,046 | $48,06150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 21 nuclear cardiology providers in New York.
Other nuclear cardiology in Brooklyn
- Nicholas PapapietroBrooklyn$2K
- Khalid HassanBrooklyn$342
- Surekha PatelBrooklyn$51
- Klaus RentropNew York$5.6M
- Diwakar JainHawthorne$105K
- John AsheldWest Islip$24K
- Brian RiegelWilliamsville$23K
- Wilbur AsheldWest Islip$11K
- Jonathan WeinsaftNew York$10K
- Rajesh RohatgiGarden City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.